
PRINCIPLES AND PRACTICE OF ENDOCRINOLOGY AND AND METABOLISM

THIRD EDITION

Kenneth L. Becker, Editor

ASSOCIATE EDITORS

John P. Bilezikian William J. Bremner Wellington Hung C. Ronald Kahn D. Lynn Loriaux Eric S. Nylén Robert W. Rebar Gary L. Robertson Richard H. Snider, Jr. Leonard Wartofsky



JANSSEN FXHIRIT 2086



ENDOCRINOLOGY AND METABOLISM

THIRD EDITION



EDITOR

Kenneth L. Becker

ASSOCIATE EDITORS
John P. Bilezikian
William J. Bremner
Wellington Hung
C. Ronald Kahn
D. Lynn Loriaux
Eric S. Nylén
Robert W. Rebar
Gary L. Robertson
Richard H. Snider, Jr.

With 330 Contributors

Leonard Wartofsky





Acquisitions Editor: Lisa McAllister Developmental Editor: Anne Snyder

Supervising Editor: Mary Ann McLaughlin

Production Editor: Shannon Garza, Silverchair Science + Communications

Manufacturing Manager: Colin Warnock

Cover Designer: Joan Greenfield

Compositor: Silverchair Science + Communications

Printer: World Color/Rand McNally

© 2001 by LIPPINCOTT WILLIAMS & WILKINS 530 Walnut Street Philadelphia, PA 19106 USA LWW.com

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright.

Printed in the USA

Library of Congress Cataloging-in-Publication Data

Principles and practice of endocrinology and metabolism / editor, Kenneth L. Becker; associate editors, John P. Bilezikian ... [et al.].--3rd ed.

p.; cm.

Includes bibliographical references and index.

ISBN 0-7817-1750-7

1. Endocrinology. 2. Endocrine glands--Diseases. 3. Metabolism--Disorders. I. Becker,

[DNLM: 1. Endocrine Diseases. 2. Metabolic Diseases. WK 100 P957 2000]

RC648 .P67 2000

616.4--dc21

00-022095

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of health care providers to ascertain the FDA status of each drug or device planned for use in their clinical practice.



PART V: THE ADRENAL GLANDS 704

There is a close relationship between neural cells of the sympathetic ganglia and chromaffin cells. Small numbers of ganglion cells can be found in the adrenal medulla, and chromaffin cells occur in the sympathetic ganglia. Hence, neoplastic disorders affecting either cell type can arise throughout this system.

The diagnosis of adrenal medullary hyperplasia depends on an increased volume of adrenal medulla in relation to the cortex. There is a diffuse nodular proliferation of normal medullary elements. This condition is seen mainly in families with multiple endocrine neoplasia type 2A and is considered a preneoplastic condition (see Chap. 188).

Neuroblastomas, ganglioneuroblastomas, and ganglioneuromas arise from neuroblasts. These tumors form a continuum from least to most differentiated and from malignant to benign. Neuroblastoma usually is a tumor of infancy and childhood, with a median incidence at the age of 2 years. It originates in the paraganglia of the sympathetic nervous system or the adrenal medulla, and 60% arise in the abdomen. Grossly, it is a multinodular tumor with areas of hemorrhage, necrosis, and cystic degeneration.²⁴ The cells are arranged in nests and contain small, dark-staining nuclei with little cytoplasm. Although the lightmicroscopic features are not necessarily distinct from those of other childhood tumors, electron microscopic examination shows characteristic cytoplasmic neurosecretory granules. Neuroblastomas usually secrete catecholamines, their metabolites, or both. Characteristically, these tumors grow rapidly and metastasize early to local lymph nodes, the liver and other abdominal organs, and bone. Although spontaneous regression or differentiation into a more benign tumor may occur, mortality is high and treatment often includes combinations of palliative surgery, radiation, and chemotherapy.²⁵ Ganglioneuroblastomas contain some mature ganglion cells and have a better prognosis. Ganglioneuromas are benign tumors arising from mature neuronal elements. 26,27

Pheochromocytomas arise from chromaffin cells. As expected from their cellular origin, 95% or more are in the abdomen, with most being in the adrenal glands.²⁸ Similar to chromaffin cells, however, they occasionally can be found anywhere along the sympathetic chain of ganglia from the base of the skull to the neck of the urinary bladder. Ten percent of patients with sporadic pheochromocytomas and 50% of those with familial pheochromocytomas have bilateral tumors. The pheochromocytoma that may occur in von Hippel-Lindau disease commonly is bilateral.^{29,30} Although only 5% to 10% are malignant, it is often impossible to distinguish benign from malignant neoplasms histologically. Pheochromocytomas are highly vascular tumors with local hemorrhage and cystic degeneration. Microscopically, they often have a chaotic pattern of pleomorphic elongated cells with prominent cytoplasmic granules (see Chap. 86). Although the light-microscopic features may not be diagnostic, electron microscopic examination demonstrates characteristic dense catecholamine secretory granules.

ADRENAL MEDULLARY HYPOFUNCTION

The adrenal medulla is affected by the same systemic diseases (tubercular and fungal infections, sarcoidosis, amyloidosis) as is the cortex and also is often the initial site of hemorrhage. Isolated adrenal medullary hypofunction is uncommon and usually occurs in the setting of diffuse autonomic insufficiency. Sparse amounts of medullary tissue may be found in some elderly persons, but no specific abnormality has been described.

REFERENCES

- Neville AM, O'Hare MJ. Histopathology of the adrenal cortex. J Clin Endocrinol Metab 1985; 14:791
- Neville AM, O'Hare MJ. The human adrenal cortex. Pathology and biology—an integrated approach. New York: Springer-Verlag, 1982
- 3. Symington T. The adrenal cortex. In: Bloodworth JMB Jr, ed. Endocrine

- JMB Jr, ed. Endocrine pathology. General and surgical. Baltimore: Williams & Wilkins, 1982:473.
- 5. Francis IR, Gross MD, Shapiro B, et al. Integrated imaging of adrenal disease. Radiology 1992; 184:1.
- Breslow MJ. Regulation of adrenal medullary and cortical blood flow. Am J Physiol 1992; 262:H1317.
- 7. Hornsby PJ. Regulation of adrenocortical function by control of growth and structure. In: Anderson DC, Winter JSD, eds. Adrenal cortex: BIMR clinical endocrinology. Boston: Butterworth, 1985:1.
- 8. Hyatt PJ. Functional significance of the adrenal zones. In: D'Agata R, Chrousos GP, eds. Recent advances in adrenal regulation and function. New York: Raven Press, 1987:35.
- 9. Winter JSD. Functional changes in the adrenal gland during life. In: D'Agata R, Chrousos GP, eds. Recent advances in adrenal regulation and function. New York: Raven Press, 1987:51.
- Copeland PM. The incidentally discovered adrenal mass. Ann Intern Med 1983; 98:940.
- 11. Doppman JL, Miller DL, Dryer AJ, et al. Macronodular adrenal hyperplasia in Cushing's disease. Radiology 1988; 166:347
- Carney JA, Young WF Jr. Primary pigmented nodular adrenocortical dis-
- ease and its associated conditions. The Endocrinologist 1992; 2:6.

 13. Ruder HJ, Loriaux DL, Lipsett MB. Severe osteopenia in young adults associated with Conditions. ciated with Cushing's syndrome due to micronodular adrenal disease. J Clin Endocrinol Metab 1974; 39:1138.
- Sakai Y, Yanase T, Hara T, et al. Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 1994; 78:36.
- 15. Del Gaudio A, Solidoro G. Myelolipoma of the adrenal gland: report of two cases with a review of the literature. Surgery 1986; 90:293
- Kelley RI, Datta NS, Dobyns WB, et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet 1986; 23:869.
- 17. Schwartz RE, Stayer SA, Pasquariello CA, et al. Anesthesia for the patient with neonatal adrenoleukodystrophy. Can J Anaesth 1994; 41:56.
- Xarli VP, Steele AA, Davis PJ, et al. Adrenal hemorrhage in the adult. Medicine (Baltimore) 1978; 57:211.
- 19. Rao RH, Vagnucci AH, Amico JA. Bilateral massive adrenal hemorrhage: early recognition and treatment. Ann Intern Med 1989; 110:227.
- Caron P, Chabanier MH, Cambus JP, et al. Definitive adrenal insufficiency due to bilateral adrenal hemorrhage and primary antiphospholipid syndrome. J Clin Endocrinol Metab 1998; 83:1437.
- 21. Stolarczykk, Ruio SI, Smolyar D, et al. Twenty-four-hour urinary free cortisol in
- patients with acquired immunodeficiency syndrome. Metabolism 1998; 47:690. Verges B, Chayanet P, Degres J, et al. Adrenal function in HIV infected patients. Acta Endocrinol (Copenh) 1989; 121:633.
- 23. Bornstein SR, Gonzalez-Hernandez JA, Erhart-Bornstein M, et al. Intimate contact of chromaffin and cortical cells within the human adrenal gland forms the basis for important intraadrenal interactions. J Clin Endocrinol Metab 1994; 78:225.
- 24. Askin FB, Perlman EJ. Neuroblastoma and peripheral neuroectodermal tumors. Am J Clin Pathol 1998; 109(4 Suppl 1):S23.
- 25. Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Curr Opin Oncol 1998; 10:43.
- Schulman H, Laufer L, Barki Y, et al. Ganglioneuroma: an 'incidentaloma' of childhood. Eur Radiol 1998; 8:582.
- 27. Fujiwara T, Kawamura M, Sasou S, Hiramori K. Results of surgery for a compound tumor consisting of pheochromocytoma and ganglioneuroblastoma in an adult; 5-year follow-up. Intern Med 2000; 39:58
- Meideiros LJ, Wolf BC, Balogh K, Federman M. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 1985; 16:580.
- Chew SL, Dacie JE, Reznik RH, et al. Bilateral pheochromocytomas in von Hippel-Lindau disease. Q J Med 1994; 87:49.
- 30. Couch V, Lindor HM, Karnes PS, Michels VV. von Hippel-Lindau disease. Mayo Clin Proc 2000; 75:265.

CHAPTER 72

SYNTHESIS AND **METABOLISM OF** CORTICOSTEROIDS

PERRIN C. WHITE

The adrenal glands are endocrinologically complex organs that are composed of two distinct endocrine tissues derived from Chan 71) The adrenal cor-



FIGURE 72-1. The steroid nucleus. The four rings are labeled A, B, C, D, and the carbons are numbered as shown. Examples are shown of steroids from each of the three structural categories of steroid hormones: the 21-carbon pregnane derivatives, the 19-carbon androstane derivatives, and the 18-carbon estrane derivatives. The names of the individual steroids shown are indicated in parentheses.

source of the steroid hormones, whereas the adrenal medulla is the source of catecholamines. Although the adrenal cortex and medulla are in close proximity, they function independently. This chapter describes the biosynthesis, metabolism, mechanisms of action, and regulation of the steroid products of the adrenal cortex.

Three major groups of hormones are produced by the adrenal cortex: *mineralocorticoids*, *glucocorticoids*, and *sex steroids*. Mineralocorticoids are produced primarily by the zona glomerulosa; glucocorticoids are produced by the zona fasciculata; and sex steroids originate primarily from the zona reticularis. The hormonal products of the adrenal cortex share cholesterol as a common precursor. Cholesterol is also the precursor for the gonadal steroids, vitamin D and derivatives, and the bile acids.

STRUCTURE AND NOMENCLATURE

Steroids have a common structure with 17-carbon atoms arranged in three six-membered rings and a fourth fivemembered ring labeled A, B, C, and D, respectively (Fig. 72-1). Each of the 17 carbons is numbered in a standard way. Two additional carbons, numbered 18 and 19, may be attached at carbons 13 and 10, respectively. Carbon atoms 20 and 21 may be attached at the 17 position. These various additions yield three steroid families: the C_{18} estranes with an aromatic ring (estrogens); the C_{19} androstanes (androgens); and the C_{21} pregnanes (corticoids and progestins) (see Fig. 72-1). The steroid nucleus lies in a plane that can be modified by the addition of substituents either above or below (Fig. 72-2). The α -substituents occur below the plane (indicated by dotted lines in Fig. 72-2) and the β -substituents lie above the plane (indicated by solid lines). The A and B rings may be attached so that the substituents at positions 5 and 10 are in either the cis or trans orientations (see Fig. 72-2).

A multiplicity of *trivial* and *systematic* or *biochemical* names exist for each steroid (Table 72-1). Between 1930 and 1950, two groups under the direction of Reichstein and of Kendall isolated most of the naturally occurring steroids. Each group labeled steroids alphabetically in the order in which they were discovered, with the result that the same compound was sometimes given two different alphabetical designations. Thus Kendall's compound A is not the same as Reichstein's




FIGURE 72-2. *Cis-trans* orientation of the steroid nucleus and location of the α - and β -substituents.

BIOSYNTHESIS

IMPORTATION INTO MITOCHONDRIA

The rate-limiting step in steroid biosynthesis is importation of cholesterol from cellular stores to the matrix side of the mitochondria inner membrane where the cholesterol side-chain cleavage system (CYP11A, adrenodoxin, adrenodoxin reductase) is located. This is controlled by the *steroidogenic acute regulatory protein* (StAR),^{2,2a} the synthesis of which is increased within minutes by trophic stimuli such as adrenocorticotropic hormone (ACTH) or, in the zona glomerulosa, by increased intracellular calcium. StAR is synthesized as a 37-kDa phosphoprotein that contains a mitochondrial importation signal peptide. However, importation into mitochondria is not necessary for StAR to stimulate steroidogenesis; to the contrary, the likeli-

TABLE 72-1.
Adrenal Steroidogenesis: Nomenclature

Nomenclature of the Major Naturally Occurring Steroid Hormones		
Common Name	Biochemical Name	Letter
Aldosterone	Pregn-4-en-11β,21-diol-18-al-3,20- dione	
Corticosterone	Pregn-4-en-11β,21-diol-3,20-dione	В
Cortisol (hydrocortisone)	Pregn-4-en-11β,17α,21-triol-3,20- dione	F
Cortisone	Pregn-4-en-17α,21-diol-3,11,20-trione	Е
Dehydroepiandrosterone (DHA, DHEA)	Androst-5-en-3β-ol-17-one	L
Deoxycorticosterone (DOC)	Pregn-4-en-21-ol-3,20-dione	
Deoxycortisol	Pregn-4-en-17\alpha,21-diol-3,20-dione	S
Estradiol	Estra-1,3,4(10)-trien-3,17β-diol	J
Progesterone	Pregn-4-en-3,20-dione	
Testosterone	Androst-4-en-17B-ol-3-one	



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

